Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

NCT02429518 is registered in ClinicalTrials.gov with Knight Therapeutics (USA) Inc as lead sponsor.

NCT NCT02429518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
Lead sponsor
Knight Therapeutics (USA) Inc
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
March 6, 2018
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucocutaneous leishmaniasis